Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Summary

The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP) CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.

Timeline

Start

2011-09

Primary completion

2016-01

Completion

2016-01

Outcome

Outcome not reported

Stopped (Enrollment): “No participants enrolled in this trial could receive the SMO antagonist as a recommended phase 2 dose was not determined by a different, concurrently-run trial.”

Drugs

Indications